72.57

0.07% 0.05

Bio Techne Corp (TECH)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split Dividend History

Bio Techne Corp stock is traded at $72.57, with a volume of 2.99M. It is up +0.07% in the last 24 hours and up +0.25% over the past month. Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.

Previous Close:

$72.52

Open:

$72.54

24h Volume:

2.99M

Relative Volume:

0.64

Market Cap:

$11.38B

Revenue:

$1.21B

Net Income/Loss:

$109.52M

P/E Ratio:

104.24

EPS:

0.6962

Net Cash Flow:

$269.60M

1W Performance:

+0.22%

1M Performance:

+0.25%

6M Performance:

+38.41%

1Y Performance:

+41.68%

1-Day Range:

$72.51

$72.63

1-Week Range:

$72.26

$72.69

52-Week Range:

$43.20

$72.69

Bio Techne Corp Stock (TECH) Company Profile

Name

Bio Techne Corp

Sector

Healthcare (1068)

Industry

Biotechnology (595)

Phone

612-379-8854

Address

614 MCKINLEY PL N E, MINNEAPOLIS, MN

Employee

3,100

Twitter

@biotechne

Next Earnings Date

2026-11-04

Latest SEC Filings

TECH's Discussions on Twitter

Compare TECH vs VRTX, REGN, MRNA, ARGX, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TECH Bio Techne Corp	72.57	11.38B	1.21B	109.52M	269.60M	0.6962
VRTX Vertex Pharmaceuticals Inc	522.38	132.40B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	796.02	81.95B	14.92B	4.42B	3.79B	41.04
MRNA Moderna Inc	194.82	77.78B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	962.22	60.20B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	199.86	42.84B	742.00K	-1.37B	-1.07B	-7.0731

Bio Techne Corp Stock (TECH) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-03-25	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Aug-21-25	Upgrade	Citigroup	Neutral → Buy
Jul-22-25	Resumed	Stephens	Overweight
Jul-09-25	Initiated	TD Cowen	Buy
May-30-25	Initiated	Wells Fargo	Overweight
Apr-09-25	Downgrade	KeyBanc Capital Markets	Overweight → Sector Weight
Mar-18-25	Initiated	Evercore ISI	Outperform
Feb-19-25	Downgrade	Robert W. Baird	Outperform → Neutral
May-22-24	Downgrade	Citigroup	Buy → Neutral
Feb-08-24	Initiated	Scotiabank	Sector Outperform
Feb-02-24	Downgrade	Stifel	Buy → Hold
Dec-07-23	Initiated	UBS	Buy
Aug-28-23	Initiated	William Blair	Outperform
Jan-10-23	Upgrade	Wells Fargo	Underweight → Equal Weight
Dec-14-22	Initiated	Deutsche Bank	Buy
Dec-12-22	Upgrade	Citigroup	Neutral → Buy
Dec-07-22	Initiated	RBC Capital Mkts	Sector Perform
Aug-25-22	Initiated	Credit Suisse	Outperform
Apr-25-22	Downgrade	Wells Fargo	Equal Weight → Underweight
Sep-15-21	Upgrade	KeyBanc Capital Markets	Sector Weight → Overweight
Mar-08-21	Upgrade	Stephens	Equal-Weight → Overweight
Feb-23-21	Upgrade	Stifel	Hold → Buy
Jan-25-21	Reiterated	The Benchmark Company	Buy
Nov-10-20	Initiated	KeyBanc Capital Markets	Sector Weight
Sep-30-20	Initiated	Atlantic Equities	Overweight
Jul-15-20	Downgrade	Stephens	Overweight → Equal-Weight
May-27-20	Downgrade	Stifel	Buy → Hold
May-14-20	Initiated	The Benchmark Company	Buy
Jan-08-20	Resumed	Stephens	Overweight
Jan-08-20	Initiated	Wells Fargo	Equal Weight
Jan-07-20	Initiated	Citigroup	Neutral
Nov-15-19	Initiated	Stifel	Buy
Jul-02-19	Upgrade	Janney	Neutral → Buy
Jan-14-19	Upgrade	Stephens	Equal-Weight → Overweight
Oct-31-18	Downgrade	Craig Hallum	Buy → Hold
Oct-17-18	Initiated	Goldman	Neutral
Jun-15-18	Initiated	Argus	Buy
Jul-13-17	Initiated	Wells Fargo	Market Perform
Feb-09-17	Initiated	Citigroup	Buy
Jan-18-17	Initiated	Deutsche Bank	Buy
Nov-10-16	Resumed	Leerink Partners	Outperform
Jan-21-15	Reiterated	Robert W. Baird	Outperform
Sep-20-13	Upgrade	Robert W. Baird	Neutral → Outperform

View All

Bio Techne Corp Stock (TECH) Latest News

01:06 AM

Form 4 Bio-Techne Corp For: 25 September By Investing.com - Investing.com Australia

01:06 AM

Sep 24, 2026

Bio-Techne (TECH) director exercises options and delivers or withholds 5,559 shares for costs or taxes. - Stock Titan

Sep 24, 2026

Bio-Techne shareholders approve $11.3 billion merger with German Merck - AKM.RU

Sep 24, 2026

What Does Shareholder Approval Mean for Bio-Techne's (NASDAQ:TECH) Merck KGaA Deal? - Kalkine Media

Sep 24, 2026

Is Bio-Techne Stock Outperforming the Nasdaq? - Barchart.com

Sep 24, 2026

Sep 23, 2026

Form 8K Bio-Techne Corp For: 23 September By Investing.com - Investing.com Canada

Sep 23, 2026

Form 8K Bio-Techne Corp For: 23 September - Investing.com India

Sep 23, 2026

Merck KGaA's USD 11.3b Bio-Techne acquisition clears final shareholder approval hurdle - AllSci

Sep 23, 2026

Bio-Techne (TECH) Opens Düsseldorf Hub As Fair Value Questions Come Into Focus - simplywall.st

Sep 23, 2026

Bio-Techne Shareholders Approve Acquisition by Merck KGaA, Darmstadt, Germany - Investing News Network

Sep 23, 2026

Bio-Techne Opens New Customer Experience Center in Düsseldorf to Accelerate Scientific Discovery and Customer Collaboration - marketscreener.com

Sep 22, 2026

Sep 21, 2026